Reports, Whitepapers & Articles

As patient engagement becomes a crucial component of pharma’s commercial strategy, the measurement of these programs is essential.

While cancer mortality has significantly dropped over time, medication adherence remains a problem—particularly among people taking oral oncolytics.

People with rare or complex conditions require a broad and more intensive level of support that includes addressing the emotional needs related to their condition.

Pharma is leaning into behavioral sciences to understand patients, personalize engagement, and motivate them to remain adherent to therapy.

In the dynamic landscape of biopharma, the year 2024 promises to be a transformative period for patient engagement. Our analysis foresees a paradigm shift, driven by advancements in digital health technologies, personalized medicine, and a heightened focus on patient-centered care.

As pharmaceutical companies channel increasing resources into their patient engagement programs, the need for robust and comprehensive measurement is imperative.

Leveraging personalized patient support alongside HUB and SP programs is a proven solution to address patient challenges.

Our November Patient Services Report includes feedback from the Momentum annual HCP survey, with the critical need for ongoing patient and HCP support at the forefront.